DIAGNOSTIC RADIOPHARMACEUTICALS AND CONTRAST MEDIA MARKET ANALYSIS
Global Diagnostic Radiopharmaceuticals and Contrast Media Market: Key Developments
In October 2022, Duchem Bio launched FACBC, the world’s first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. FACBC had already received approval in the U.S. and EU in 2016 and 2017, respectively, and has been applied to about 196,000 patients.
In January 2021, QSAM Biosciences Inc. announced favorable results from a study to evaluate the radioactive impurity levels in its flagship drug candidate Samarium-153-DOTMP (aka CycloSam). The results of this study are positive indicators about the safety profile and potential expanded uses of CycloSam if ultimately approved for commercial usage.
In May 2020, the U.S. Food and Drug Administration (FDA) approved the radiopharmaceutical, flortaucipir F18 of Avid Radiopharmaceuticals, which is indicated to help image a distinctive characteristic of Alzheimer’s disease.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
